AGE
Income statement / Annual
Last year (2023), AgeX Therapeutics, Inc.'s total revenue was $142,000.00,
an increase of 317.65% from the previous year.
In 2023, AgeX Therapeutics, Inc.'s net income was -$14.80 M.
See AgeX Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$142,000.00
|
$34,000.00
|
$144,000.00
|
$1.87 M
|
$1.73 M
|
$1.40 M
|
$1.40 M
|
| Cost of Revenue |
$171,000.00 |
$13,000.00 |
$19,000.00 |
$158,000.00 |
$244,000.00 |
$364,000.00 |
$168,000.00 |
| Gross Profit |
-$29,000.00 |
$21,000.00 |
$125,000.00 |
$1.71 M |
$1.48 M |
$1.03 M |
$1.24 M |
| Gross Profit Ratio |
-0.2 |
0.62 |
0.87 |
0.92 |
0.86 |
0.74 |
0.88 |
| Research and Development
Expenses |
$603,000.00
|
$1.03 M
|
$1.46 M
|
$4.98 M
|
$5.90 M
|
$6.63 M
|
$5.78 M
|
| General & Administrative
Expenses |
$9.33 M
|
$5.97 M
|
$6.71 M
|
$7.40 M
|
$8.14 M
|
$5.65 M
|
$3.87 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$9.33 M
|
$5.97 M
|
$6.71 M
|
$7.40 M
|
$8.14 M
|
$5.65 M
|
$3.87 M
|
| Other Expenses |
$11,000.00 |
$13,000.00 |
$448,000.00 |
$44,000.00 |
$294,000.00 |
$183,000.00 |
$38,000.00 |
| Operating Expenses |
$9.93 M |
$7.00 M |
$8.16 M |
$12.38 M |
$14.04 M |
$12.28 M |
$9.65 M |
| Cost And Expenses |
$10.10 M |
$7.01 M |
$8.18 M |
$12.54 M |
$14.29 M |
$12.64 M |
$9.82 M |
| Interest Income |
$0.00 |
$3.34 M |
$1.10 M |
$404,000.00 |
$29,000.00 |
$0.00 |
$0.00 |
| Interest Expense |
$4.90 M |
$3.34 M |
$1.10 M |
$0.00 |
$0.00 |
$116,000.00 |
$0.00 |
| Depreciation &
Amortization |
$131,000.00
|
$145,000.00
|
$579,000.00
|
$1.68 M
|
$951,000.00
|
$535,000.00
|
$682,000.00
|
| EBITDA |
-$9.83 M
|
-$6.98 M
|
-$7.93 M
|
-$9.15 M
|
-$11.61 M
|
-$10.71 M
|
-$9.49 M
|
| EBITDA Ratio |
-69.22 |
-200.88 |
-51.81 |
-4.81 |
-6.72 |
-7.67 |
-6.76 |
| Operating Income Ratio
|
-70.14
|
-205.15
|
-55.83
|
-5.71
|
-7.27
|
-8.06
|
-4.75
|
| Total Other
Income/Expenses Net |
-$4.85 M
|
-$3.55 M
|
-$649,000.00
|
$272,000.00
|
$323,000.00
|
$3.51 M
|
$1.78 M
|
| Income Before Tax |
-$14.81 M |
-$10.52 M |
-$8.58 M |
-$11.13 M |
-$12.24 M |
-$7.73 M |
-$6.64 M |
| Income Before Tax Ratio
|
-104.3
|
-309.47
|
-59.6
|
-5.96
|
-7.08
|
-5.54
|
-4.73
|
| Income Tax Expense |
-$8,000.00 |
$152,000.00 |
$1.64 M |
-$150,000.00 |
$148,000.00 |
$3.51 M |
-$1.80 M |
| Net Income |
-$14.80 M |
-$10.67 M |
-$10.22 M |
-$10.98 M |
-$12.38 M |
-$7.50 M |
-$6.58 M |
| Net Income Ratio |
-104.25 |
-313.94 |
-70.97 |
-5.88 |
-7.17 |
-5.37 |
-4.69 |
| EPS |
-13.72 |
-9.89 |
-9.49 |
-10.25 |
-11.69 |
-7.56 |
-6.46 |
| EPS Diluted |
-13.72 |
-9.89 |
-9.49 |
-10.25 |
-11.69 |
-7.56 |
-6.46 |
| Weighted Average Shares
Out |
$1.08 M
|
$1.08 M
|
$1.08 M
|
$1.07 M
|
$1.06 M
|
$992,721.00
|
$1.02 M
|
| Weighted Average Shares
Out Diluted |
$1.08 M
|
$1.08 M
|
$1.08 M
|
$1.07 M
|
$1.06 M
|
$992,721.00
|
$1.02 M
|
| Link |
|
|
|
|
|
|
|
